Literature DB >> 3106085

Amiloride selectively inhibits the urokinase-type plasminogen activator.

J D Vassalli, D Belin.   

Abstract

The diuretic drug amiloride, an inhibitor of Na+ uptake, competitively inhibits the catalytic activity of the urokinase-type plasminogen activator (u-PA), with a Ki of 7 X 10(-6) M. Generation of plasmin, cleavage of peptide substrates, and interaction of u-PA with a specific macromolecular proteinase inhibitor are all prevented in the presence of the drug. In contrast, amiloride does not affect the activity of either tissue-type plasminogen activator, plasmin, plasma kallikrein or thrombin. The inhibition of u-PA by amiloride may be related to the previously reported inhibition of u-PA-type enzymes by Na+. Amiloride or related compounds could prove useful in selectively controlling u-PA-catalyzed extracellular proteolysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106085     DOI: 10.1016/0014-5793(87)80039-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  80 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

2.  Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9.

Authors:  M G Martínez-Hernández; L A Baiza-Gutman; A Castillo-Trápala; D Randall Armant
Journal:  Reproduction       Date:  2010-11-12       Impact factor: 3.906

3.  Axonal regrowth after spinal cord injury via chondroitinase and the tissue plasminogen activator (tPA)/plasmin system.

Authors:  Noreen Bukhari; Luisa Torres; John K Robinson; Stella E Tsirka
Journal:  J Neurosci       Date:  2011-10-19       Impact factor: 6.167

4.  Plasmin in nephrotic urine activates the epithelial sodium channel.

Authors:  Per Svenningsen; Claus Bistrup; Ulla G Friis; Marko Bertog; Silke Haerteis; Bettina Krueger; Jane Stubbe; Ole Nørregaard Jensen; Helle C Thiesson; Torben R Uhrenholt; Bente Jespersen; Boye L Jensen; Christoph Korbmacher; Ole Skøtt
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

Review 5.  Urinary serine proteases and activation of ENaC in kidney--implications for physiological renal salt handling and hypertensive disorders with albuminuria.

Authors:  Per Svenningsen; Henrik Andersen; Lise H Nielsen; Boye L Jensen
Journal:  Pflugers Arch       Date:  2014-12-09       Impact factor: 3.657

6.  Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse.

Authors:  M A Olman; N Mackman; C L Gladson; K M Moser; D J Loskutoff
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  A unique modulator of endoplasmic reticulum stress-signalling pathways: the novel pharmacological properties of amiloride in glial cells.

Authors:  Toru Hosoi; Ayaka Kume; Kayo Otani; Tatsuya Oba; Koichiro Ozawa
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

8.  Amiloride modulates urokinase gene expression at both transcription and post-transcription levels in human colon cancer cells.

Authors:  Y Wang; J Dang; X Liang; W F Doe
Journal:  Clin Exp Metastasis       Date:  1995-05       Impact factor: 5.150

9.  Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.

Authors:  D M Evans; K Sloan-Stakleff; M Arvan; D P Guyton
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

10.  Role of the TMPRSS2-ERG gene fusion in prostate cancer.

Authors:  Scott A Tomlins; Bharathi Laxman; Sooryanarayana Varambally; Xuhong Cao; Jindan Yu; Beth E Helgeson; Qi Cao; John R Prensner; Mark A Rubin; Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.